The global Peripheral Blood Mononuclear Cells market size is estimated at xxx million USD with a CAGR of 10.9% during the forecasted period from 2021-2028.
Peripheral Blood Mononuclear Cells(PBMC) originate from hematopoietic stem cells (HSCs) that inhabit in the bone marrow. PBMCs are extensively used in healthcare sector for clinal and research activities and hence are important for various studies. They are considered as a vital component of immune system as they can produce a reaction to invaders arriving the human body and existing cells that have suffered a change into a tumorous cell type.
The key factor driving the global Peripheral Blood Mononuclear Cells market is attributed to increasing research & development activities. PBMC is necessary to conduct findings in the laboratory and has a wide range of applications in medicine and research. Some of the uses where PBMC is basic comprise vaccine development, high-throughput screening, autoimmune disease, transplant immunology, and so on. In addition, growing number of diseases is projected to augment the growth of this market during the forecast period.
On the other, lack of research activities in emerging economies can constrain the market growth. This is mainly due to factors such as deficient resources and inadequate infrastructure, lack of funding, and skilled professionals to support research activities.
The increasing use of Peripheral Blood Mononuclear Cells (PBMC) for research and clinical studies is boosting the global Peripheral Blood Mononuclear Cells market.
Peripheral Blood Mononuclear Cells are important tools for studies in Immunology infectious disease, hematological malignancies, vaccine development, transplant immunology, high-throughput screening, and Neovascularization. It helps to improve limb ischemia and in cell therapy to repair ischemic and infracted myocardium, Human body defense mechanisms critical in the immune system to fight bacterial and viral infections, and function as immune surveillance network to kill tumor cells. It is also used for the secretion of cytokines to regulate immune response and inflammation. PBMCs, as a model system, has been widely used to study metabolic and autoimmune diseases.
Prostate cancer is the second leading cause of cancer deaths in men globally, the use of Peripheral Blood Mononuclear Cells for Prostate Cancer Studies. For example, in 2010, the FDA approved the first autologous cellular immunotherapy drug for treating patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The drug, known as sipuleucel-T, is manufactured via a unique process that activates PBMCs with a fusion protein. This study looked at a larger sample of data from three phase 3 trials to gain a greater understanding of how the therapy engages the immune system via PBMC activation.
Lack of research practices in developing nations is a major drawback hampering the global Peripheral Blood Mononuclear Cells market. As the developing countries have insufficient resources or a weak infrastructure to support their research. The Global Forum for Health Research reports that only 10% of research funding is spent on 90% of the worldâs health problems, therefore using funds from developed countries to address health disparities in the lesser developed countries.
Based on product type, the global Peripheral Blood Mononuclear Cells market is broadly segmented as Fresh Peripheral Blood Mononuclear Cells, Cryopreserved Peripheral Blood Mononuclear Cells, Peripheral Blood Mononuclear Cell Isolation & Viability Kits, and Others. In 2018 Cryopreserved Peripheral Blood Mononuclear Cells is the dominant segment, and it accounts for approximately XX% of the market.
Cryopreserved peripheral blood mononuclear cells are useful in clinical trials that have low end-point frequencies because they allow the immunologic assays to be performed after the conclusion of the studies when all the endpoints have already been identified. PBMCs possess stable viability and function over prolonged periods when adequately stored, and can be used in substitution of fresh PBMCs for several phenotypic and functional assays.
The use of cryopreserved peripheral blood mononuclear cells (PBMC) for immunologic assays has intensely increased in recent years. Cryopreserved PBMC are particularly useful in clinical trials with low end-point frequencies because they allow the immunologic assays to be performed after the conclusion of the studies when all the endpoints have already been identified. Additionally, the use of cryopreserved PBMC allows all assays to be performed in a single laboratory, eliminating interlaboratory variability, which has been a confounder in some studies. The availability of cryopreserved peripheral blood mononuclear cells (PBMC) in the market is boosting the global peripheral blood mononuclear cells market. For instance, on September 20, 2018, StemExpress, a Folsom, California based leading supplier of human biospecimens, have introduced frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications, such as cancer, autoimmune diseases, device development, and other applications.
The global Peripheral Blood Mononuclear Cells market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America is dominating the global Peripheral Blood Mononuclear Cells market, due to the increasing capacity for peripheral blood mononuclear cell (PBMC) storage. For instance, May 23, 2018, LabConnect, LLC, a leading global provider of central laboratory and support services for biopharmaceutical, medical device and contract research organizations, has completed phase one of an 11,000+ square foot facility expansion in Johnson City, Tennessee. The new space will increase the capacity for peripheral blood mononuclear cell (PBMC) processing and allow LabConnect to serve its clients better. It is estimated that the phase three will be finished soon for better clinical studies
The North America Peripheral Blood Mononuclear Cells market size was XX million USD in 2018, and it will be XXX million USD in 2026, with a CAGR XX% from 2019 to 2026.
Europe has shown significant growth in 2018, due to the introduction of new product in the market. For instance, June 14, 2017, Miltenyi Biotec, has introduced the new MACSprep PBMC Isolation Kit, that allows the preparation of highly pure peripheral blood mononuclear cells (PBMCs) from whole human blood without density gradient centrifugation in only 25 min. The kit is ideal for the processing of small blood samples.
The major players include BioIVT, Biovision, Atzlabs, Creative Bioarray, CELL Applicaton, Inc., Miltenyl Biotec, Precision Medicine Group, and others
The implementation of peripheral blood mononuclear cells (PBMC) in the research study is boosting the global Peripheral Blood Mononuclear Cells market. For instance, September 5, 2018, SGS, a life sciences, pharmaceutical, clinical and bioanalytical contract solutions provider, has successfully executed advanced techniques for the collection and use of peripheral blood mononuclear cells (PBMCs) for early phase clinical trials at its clinical pharmacology unit (CPU) in Antwerp, Belgium, and is also further strengthening its offer in the areas of infectious disease therapeutics and vaccines. PBMCs are already widely used to study various aspects of pathology and biology in vitro but are also used in clinical studies in, as well as infectious diseases, hematological malignancies, vaccine development, and transplant immunology.
Global Peripheral Blood Mononuclear Cells Market
- Consumption by Regions
- North America
- Rest of the World
- Segment by Product Type
- Fresh Peripheral Blood Mononuclear Cells
- Cryopreserved Peripheral Blood Mononuclear Cells
- Peripheral Blood Mononuclear Cell Isolation & Viability Kits
- Segment by Application
- Human Heme-Oncology PBMCs
- Human Breast Cancer PBMCs
- Human Rheumatoid Arthritis PBMCs
- Human Hepatitis C Virus (HCV) PBMCs
- Human Sickle Cell Disease PBMCs